Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Latest News
    • 15 minutes laser is...

    15 minutes laser is new first line treatment of Glaucoma

    Written by Dr. Kamal Kant Kohli Kohli Published On 2019-03-13T19:20:04+05:30  |  Updated On 13 March 2019 7:20 PM IST
    15 minutes laser is new first line treatment of Glaucoma

    A 15 minutes laser procedure known as selective laser trabeculoplasty is the new first line treatment of glaucoma.


    According to a new study, using a laser-based treatment on newly diagnosed cases of glaucoma is more effective cost and success wise than the current method of using intraocular pressure lowering eye drops.The report, which appears in the Lancet, says the laser technique – known as selective laser trabeculoplasty or SLT – should replace the prescribing of eye drops, the current favoured way to treat glaucoma.


    Glaucoma is one of the world’s leading causes of blindness. In the UK, it affects about 2% of the population over the age of 40 and is most often triggered when tubes in the eye become blocked, preventing fluid from draining from the eye properly. The rise in intra ocular pressure can damage the optic nerve leading to blindness.


    There are a number of side-effects associated with the drops include increased risks of developing eye cataracts in later life, as well as a reduced pulse rate and fatigue.But Physicians' habits die hard, and the simplistic algorithm of giving drops first, then laser, then surgery is engrained in practice and teaching.


    The researchers at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology carried out a three-year trial,.In the largest ever trial of its kind,in all 718 patients newly-diagnosed with glaucoma or ocular hypertension were assigned one of two treatment pathways.


    One pathway was the current standard treatment of administering eye drops designed to lower intraocular pressure (IOP) and the other involved a procedure called selective laser trabeculoplasty (SLT), a quick procedure which is done in the clinic using anaesthetic eye drops and which lowers IOP by using lasers to increase the ease with which fluid can leave the eye.


    Patients who received laser treatment were more regularly at the target IOP. There was also less chance of treatment escalation being required and a lower need for both glaucoma surgery and cataract extractions than was required by patients who received the eye drops.


    The efficacy of laser trabeculoplasty as treatment for open-angle glaucoma is established .It was considered as first-line treatment in 1990 in the Glaucoma Laser Trial.It showed that in patients with newly diagnosed primary open-angle glaucoma, argon laser trabeculoplasty was an effective and safe first-line therapy compared to topical timolol.


    Selective laser trabeculoplasty, which has the advantage of causing less target tissue disruption, superseded argon laser trabeculoplasty as the laser treatment of choice.


    Randomised trials compared selective laser trabeculoplasty and latanoprost,and established selective laser trabeculoplasty as a safe and effective first-line treatment.


    eye dropsfirst lineglaucomaLasernewselectivetrabeculoplastytreatment

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok